Reprint

Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches

Edited by
April 2022
368 pages
  • ISBN978-3-0365-3036-9 (Hardback)
  • ISBN978-3-0365-3037-6 (PDF)

This book is a reprint of the Special Issue Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Dear colleagues,

This Special Issue, “Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches”, focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions.

Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment.

The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host–immune reactions near tumor environments.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
endothelial cells; oxidative stress; inflammageing; endothelial dysfunction; aldehyde dehydrogenase-2; cardiovascular disease; neurovascular disease; endothelial dysfunction; vascular inflammation; APE1/Ref-1; cardiovascular diseases; subcellular localization; serological biomarkers; atherosclerosis; aerobic exercise; endothelial dysfunction; PCSK9; LOX-1; endothelial dysfunction; insulin resistance; macrophage polarity; serum γ-glutamyltransferase; endothelial dysfunction; essential hypertension; atherosclerosis; cardiovascular risk factors; angiogenesis; nargenicin A1; compound 9; VEGF; VEGFR2; HIF-1α; electronegative low-density lipoprotein; LDL(–); L5 LDL; oxidized LDL; oxLDL; cardiovascular disease; atherosclerosis; ADMA; arginine; arginine paradox; BH4; blood pressure; COVID-19; dietary supplements; endothelial dysfunction; endothelium; eNOS uncoupling; heart failure; hypertension; L-arginine; myocardial infarction; NADPH; nitric oxide; oxidative stress; peripheral artery disease; APE1/Ref-1; atherosclerosis; ApoE knockout mouse; atorvastatin; VCAM-1; galectin-3; neutrophil/lymphocyte ratio; electronegative LDL; LDL(−); L5 LDL; oxidized LDL; oxLDL; lectin-like oxLDL receptor-1; LOX-1; dyslipidemia; endothelial dysfunction; atherosclerosis; cardiovascular disease; chronic venous insufficiency; prolyl oligopeptidase (POP); inflammation; angiogenesis; endothelial disfunction; lung disease; endothelial to mesenchymal transition; pulmonary hypertension; pulmonary fibrosis; metformin; endothelial dysfunction; diabetes; CV risk; diabetes; hyperglycemia; glycated lipoproteins; glycated LDL; glycated HDL; endothelial cell dysfunction; molecular mechanisms; epigenetic factors; therapeutic approaches; pulmonary hypertension; endothelial dysfunction; vasoactive factors; EndoMT; inflammation; TGF-β; epigenetics; endothelial cell; glycolysis; metabolism; angiogenesis; pathological angiogenesis; tumor microenvironment; MRI (magnetic resonance imaging); endothelial dysfunction; high-fat diets; plaque burden; low-level laser therapy; phototherapy; endothelium; vascular disease; healing; angiogenesis; ischemia; hypertension; inflammation; nitric oxide; vascular calcification; chronic kidney disease; CKD; uremic toxins; hyperphosphatemia; vascular smooth muscle cells; VSMCs; macrophages; endothelium; n/a